Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
about
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyReal-life treatment of metastatic colorectal cancer with regorafenib: a single-centre review.Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Informed Consent: A Clinical Trials Perspective.The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review.Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
P2860
Q38679229-83788CAB-C25F-42C3-BE3D-C5069A69C0B0Q40046547-00543FFB-BC4F-466C-B4C3-13A2FFE7DFEFQ41559404-1E403E26-110B-43CC-B034-8248DC44B250Q42407052-0DE4E340-83E7-4160-8EB4-C587C84DF813Q42704100-81079D8B-9304-40D8-BD1D-89FF15B475D4Q47094732-226183D2-1328-4714-92D2-10DD01E2E42EQ49922743-ED56F05A-A19E-4EDD-9FBC-A2AF7432A672Q52643766-E89EDF18-9E30-4F49-9A24-FDA5215FF275Q55421771-FFBA4D61-2A0F-4CB7-BD67-5169DFC0B38BQ57788662-0C434931-0D65-4DD7-BDC4-1E29B3BE1A7F
P2860
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Survival, safety, and prognost ...... in a compassionate use program
@ast
Survival, safety, and prognost ...... in a compassionate use program
@en
type
label
Survival, safety, and prognost ...... in a compassionate use program
@ast
Survival, safety, and prognost ...... in a compassionate use program
@en
prefLabel
Survival, safety, and prognost ...... in a compassionate use program
@ast
Survival, safety, and prognost ...... in a compassionate use program
@en
P2093
P2860
P50
P1433
P1476
Survival, safety, and prognost ...... in a compassionate use program
@en
P2093
Andrew Kramar
Antoine Adenis
Bernard Paule
Jean-Marc Phelip
Jennifer Wallet
Laurent Mineur
Louis-Marie Dourthe
Pascal Burtin
Pierre-Luc Etienne
Stéphanie Clisant
P2860
P2888
P356
10.1186/S12885-016-2440-9
P407
P577
2016-07-07T00:00:00Z
P6179
1044485147